Detalhe da pesquisa
1.
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
Lancet
; 402(10403): 720-730, 2023 08 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37364590
2.
Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials.
Diabetes Obes Metab
; 23(12): 2785-2794, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34472698
3.
Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
JAMA
; 321(15): 1466-1480, 2019 04 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30903796
4.
Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials.
J Diabetes Investig
; 13(6): 975-985, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35112504
5.
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Lancet Diabetes Endocrinol
; 8(5): 377-391, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32333875
6.
Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
Lancet Diabetes Endocrinol
; 8(5): 392-406, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32333876
7.
Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial.
Diabetes Care
; 42(7): 1255-1262, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31076415